GRCE

Grace Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website -
Employees(FY) -
ISIN US00439U1043

Performance

+0.61%

+6.45%

+25.95%

+20.92%

+14.19%

YTD

+41.63%

Profile

Advanced Technical Analysis

Technical Analysis of GRCE 2024-12-02

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 71 further supports this positive outlook. However, the Oscillators Score of 53 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GRCE

Stock Rank

Recent News & Updates

2024-11-12 19:00
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update(Globenewswire)
2024-10-29 20:00
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024(Globenewswire)
2024-10-24 20:00
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.(Globenewswire)
2024-09-24 19:30
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104(Globenewswire)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Yahoo Finance)
2024-09-11 20:00
Acasti to Present at the Life Sciences Investor Forum(Globenewswire)
2024-09-04 22:35
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-09 02:52
ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025(Investorplace)
2024-08-08 20:00
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update(Globenewswire)
2024-07-09 21:40
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?(Zacks)
2024-06-27 04:05
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial(Globenewswire)
2024-06-21 01:53
ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024(Investorplace)
2024-06-20 20:00
Acasti Announces Year-End 2024 Financial Results, Provides Business Update(Globenewswire)
2024-06-18 00:31
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024(Investorplace)
2024-05-28 04:05
Acasti Pharma to Attend BIO International Convention 2024(Globenewswire)
2024-05-22 18:45
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom(Investorplace)
2024-03-24 03:54
12 Best Biotech Penny Stocks to Invest In(Insidermonkey)
2024-02-11 19:00
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-02-11 18:57
Acasti: Fiscal Q3 Earnings Snapshot(Yahoo Finance)
2024-01-31 19:00
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial(Globenewswire)
2023-12-12 19:00
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024(Globenewswire)
2023-11-12 19:20
Acasti: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
2023-11-12 19:00
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2023-10-22 20:00
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial(Globenewswire)
2023-10-03 20:00
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)(Globenewswire)
2023-09-25 20:00
Acasti Announces $7.5 Million Private Placement Equity Financing(Yahoo Finance)
2023-09-05 20:00
Acasti to Participate in the H.C. Wainwright Global Investment Conference(Yahoo Finance)
2023-08-22 15:49
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)(Yahoo Finance)
2023-08-21 21:19
TEVA to Pay $250 Million to Settle Price-Fixing Charges(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.